EVE Health Group Elevates Ben Rohr to CEO to Drive Commercial Growth

Leadership Shift Targets Commercial Momentum

EVE Health Group Limited (ASX:EVE) has appointed Ben Rohr as its new Chief Executive Officer, effective immediately, marking a strategic pivot toward accelerating the commercialisation of its pharmaceutical portfolio. Rohr, previously Chief Operating Officer, has been a key driver behind the integration of the Nextract acquisition and the advancement of EVE’s flagship products, Dyspro® and Libbo®, positioning him as a natural fit to lead the company’s next growth phase.

The appointment replaces Damian Wood in the CEO role, who will transition to Head of Regulatory and Medical Affairs, focusing exclusively on regulatory strategy, clinical development, and medical affairs. This realignment aims to balance strong commercial leadership with dedicated regulatory expertise, reflecting the company’s dual priorities as it prepares for broader market rollout.

Rohr’s Commercial Track Record and Incentives

Rohr’s promotion comes on the back of his instrumental role in executing EVE’s strategy, particularly in integrating the Nextract solubility enhancement technology, which underpins the company’s reformulated drug candidates. His leadership extends to advancing Dyspro®, a cannabinoid-based pastille targeting dysmenorrhoea and endometriosis, and Libbo®, an oral dissolving film for erectile dysfunction, both designed for rapid onset and improved patient convenience. These products leverage proprietary delivery technologies to address sizable unmet needs in global markets.

Rohr’s remuneration package includes a base salary of $220,000 plus superannuation and retention of 2.9 million unlisted options exercisable at $0.06, issued under the company’s Employee Incentive Plan in December 2025. This package underscores the board’s commitment to incentivising disciplined growth and successful commercial execution.

Strategic Implications of the Leadership Restructure

Chairman Rod Hannington emphasised Rohr’s strong leadership and commercial focus as critical assets for navigating EVE’s evolving landscape. The restructuring delineates responsibilities clearly, allowing Wood to concentrate on regulatory approvals and clinical programs, which remain pivotal as EVE seeks to secure ARTG registration and expand market access through digital health platforms like ReclaimMyCycle.com and StiffIssue.com.

This leadership evolution follows a series of capital raises and product development milestones, including the successful acquisition of Nextract IP and progress under the SAS-B regulatory pathway, which have laid the groundwork for commercial rollout. Rohr’s elevation signals the board’s intent to leverage this momentum into disciplined revenue growth and operational scalability, building on the company’s recent Nextract acquisition integration and pharmaceutical product rollout plans.

With the global markets for dysmenorrhoea, endometriosis, and erectile dysfunction running into billions, EVE’s focus on proprietary formulations and delivery technologies positions it to capture significant share if regulatory and commercial execution proceeds smoothly.